Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
07 mars 2023 02h00 HE
|
Verona Pharma plc
Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST /...
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
21 févr. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
20 déc. 2022 02h00 HE
|
Verona Pharma plc
Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission...
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
19 déc. 2022 16h01 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09 nov. 2022 02h00 HE
|
Verona Pharma plc
Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m....
Verona Pharma Announces November 2022 Investor Conference Participation
02 nov. 2022 03h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following...
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update
26 oct. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
17 oct. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it has entered into a debt financing facility (“debt...
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
14 oct. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces additional exacerbation* subgroup analyses from the Phase 3...
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
29 août 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...